LY3295668 not checked

Eli Lilly · AK-01

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Neuroblastoma
Main trialPhase 1
“The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.”In the company’s words, NCT04106219 on ClinicalTrials.gov
Other names
AK-01 · Erbumine

Other drugs for Neuroblastoma

All 12 drugs for Neuroblastoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 13 Apr 2022 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Phase 1/2Completed 20 Apr 2020 A Study of AK-01 (LY3295668) in Solid Tumors
Phase 1Completed 2 Jun 2020 A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow LY3295668

Following is part of Solo: you see every change to LY3295668 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in